undamentalytics Newsletter
Sign in

Xeris Biopharma Holdings, Inc. cash flow statement

In fiscal 2025, Xeris Biopharma Holdings, Inc.'s operations generated $28.6m of cash; it spent $0 on capital projects, leaving free cash flow of $28.6m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−81−96−103−47−372957
Depreciation and amortisation1111111
Stock-based pay8111211182228
Capital spending010000—
Free cash flow−81−97−103−47−3729—
Free cash flow after stock pay−89−108−115−58−556—
Shares issued66273000——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EOLS vs XERSIRWD vs XERSHROW vs XERSINVA vs XERS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xeris Biopharma Holdings, Inc.